Login / Signup
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma.
Reem Karmali
Frédérique St-Pierre
Leo I Gordon
Published in:
Future oncology (London, England) (2023)
Keyphrases
</>
diffuse large b cell lymphoma
epstein barr virus
tyrosine kinase
type diabetes
skeletal muscle
adipose tissue
hodgkin lymphoma
glycemic control